Discovery of the TKTL1 gene
Thanks to the discovery and study of the TKTL1 gene, a marker for the early detection of malignant tumours is now available, as well as a target for treatment with benfo-oxythiamine.
Blessing and curse of the TKTL1 sugar-fat metabolism
How it can both protect us and make us ill. Mutation in the TKTL1 gene promotes nerve cell formation (blessing). Activation of the TKTL1 metabolism also leads to malignant tumour cells (curse).
Epigenetic control of gene expression at the mRNA level
New form of epigenetics is significantly controlled by the metabolic products lactic acid and acetyl-CoA of the TKTL1 sugar-fat metabolism. Significant for DNA repair, the immune system and longevity.
Message from Dr Johannes Coy to Prof. Svante Pääbo
for the 2022 Nobel Prize in Medicine. The paleogenetics founded by Pääbo and the basic research of the Max Planck Society underline, among other things, the importance of TKTL1 for the diagnosis and treatment of diseases.
We will rethink medicine – TKTL1 Talk with Dr Johannes
Coy
Big TKTL1 interview with Dr Johannes Coy
The big exclusive interview with Dr. Johannes Coy about the gene he discovered, TKTL1, and its importance for our lives.
Lecture by Dr Johannes Coy on “Sugar versus intelligent sugars:
at the launch event of the “BE ACCEPTED” initiative for women with cancer, supported by the European Society of Radiology (ESR) as part of ECR 2022.
EDIM technologyEpitope detection in monocytesThe development of Epitope Detection in Monocytes (EDIM), a new flow cytometry-based method for detecting biomarkers in blood, sets the stage for the future development of numerous new diagnostic tests. |
PanTum DetectBlood test for the early detection of tumoursUsing EDIM technology to detect the biomarkers DNaseX (Apo10) and TKTL1, a unique new blood test was created for the early detection of tumours. |
Benfo-oxythiamineInhibitor against chemoresistant cancer cellsThe establishment of the vitamin B1 derivative benfo-oxythiamine (B-OT) opens up a new treatment option that resensitises resistant tumours to established cancer drugs. |